Promising nerve pain drug trial for MGUS patients withdrawn before start
NCT ID NCT06046287
First seen Nov 01, 2025
Summary
This study aimed to test if daratumumab could improve nerve damage (peripheral neuropathy) in people with a blood condition called MGUS. Participants would have received weekly injections for two months, then biweekly for four more months. However, the trial was withdrawn before enrolling anyone, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.